Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN)

Reumatismo

Volumn 60, Issue 4, 2008, Pages 290-295

  Sarzi Puttini, Piercarlo ^a   Antivalle, M ^a   Marchesoni, A ^b   Favalli, E G ^b   Gorla, R ^c   Filippini, M ^c   Caporali, R ^d   Bobbio Pallavicini, F ^d   Montecucco, C ^d   Atzeni, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Rheumatology and Clinical Immunology Unit   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Italian Society of Rheumatology (Societ Italiana di Reumatologia SIR ); Lombardy Rheumatology Network (LORHEN) registry; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BONE INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; REGISTRATION; RHEUMATOID ARTHRITIS; SYNOVITIS; SYSTEMIC DISEASE; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; ITALY; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTORS;

EID: 61549086004     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-9.
2. Moreland LW, Baumgartner SW, Schiff MH, Tindal EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumour necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
4. Hamilton K, Clair EW. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother 2000; 1: 1041-52.
5. Valesini G, Montecucco C, Cutolo M. Anti-TNF treatment for rheumatoid arthritis. Clin Exp Rheumatol 2006, 24: 413-23.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. Van Riel PLCM, van Gestel AM, Scott DL, on behalf of the EULAR standing committee for international clinical studies including therapeutic trials. The EULAR handbook of clinical assessment in rheumatoid arthritis. Alpen an den Rijn, The Netherlands: Van Zuiden Communications, 2000.
8. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, et al. The Italian version of the functional disability index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies in rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 123-8.
9. Apolone G, Moscone P. Come usare il questionario sullo stato di salute SF-36 (versione italiana). Progetto IQOLA. Istituto di Ricerche Farmacologiche "Mario Negri", 1996.
10. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004; 43: 1252-5.
11. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
12. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burnester GR, Zink A. Clinical and functional remission: even though biologics are superior to conventional DMARD overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8(3): R66.
13. Silman A, Symmons D, Scott DGI, Griffiths I. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 (Suppl. II): ii28-ii29.
14. Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
15. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, for the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
16. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
17. Van Vollenhoven RF, Askling J. Rheumatoid arthritis registers in Sweden. Clin Exp Rheum 2005; 23 (Suppl 39): S195-S200.
18. Kremer JM. The CORRONA database. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S172-7.
19. Pavelka K, Gatterova J, Tegzova D, Jarasova K, Tomasova Studynkova J, et al.. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin Exp Rheum 2007; 25: 540-5.